JP4460830B2 - インドール誘導体 - Google Patents

インドール誘導体 Download PDF

Info

Publication number
JP4460830B2
JP4460830B2 JP2002551528A JP2002551528A JP4460830B2 JP 4460830 B2 JP4460830 B2 JP 4460830B2 JP 2002551528 A JP2002551528 A JP 2002551528A JP 2002551528 A JP2002551528 A JP 2002551528A JP 4460830 B2 JP4460830 B2 JP 4460830B2
Authority
JP
Japan
Prior art keywords
indol
amino
acetyl
methyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002551528A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004517098A (ja
JP2004517098A5 (enExample
Inventor
デメーン，デリック，アンソニー
ギブリン，ジェラード，マルティン，ポール
ホスキン，レイチェル，エリザベス
イングリス，グラハム，ジョージ，アダム
レウェル，シャオ，キング
マクドナルド，シモン，ジョン，ファウセット
メイソン，アンドリュー，マックマートリー
スワーブリック，マーティン，エドワード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2004517098A publication Critical patent/JP2004517098A/ja
Publication of JP2004517098A5 publication Critical patent/JP2004517098A5/ja
Application granted granted Critical
Publication of JP4460830B2 publication Critical patent/JP4460830B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
JP2002551528A 2000-12-21 2001-12-20 インドール誘導体 Expired - Fee Related JP4460830B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0031315.5A GB0031315D0 (en) 2000-12-21 2000-12-21 Indole derivatives
PCT/GB2001/005701 WO2002050031A1 (en) 2000-12-21 2001-12-20 Indole derivatives

Publications (3)

Publication Number Publication Date
JP2004517098A JP2004517098A (ja) 2004-06-10
JP2004517098A5 JP2004517098A5 (enExample) 2005-12-22
JP4460830B2 true JP4460830B2 (ja) 2010-05-12

Family

ID=9905643

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002551528A Expired - Fee Related JP4460830B2 (ja) 2000-12-21 2001-12-20 インドール誘導体

Country Status (9)

Country Link
US (1) US7288564B2 (enExample)
EP (1) EP1343757B1 (enExample)
JP (1) JP4460830B2 (enExample)
AT (1) ATE353875T1 (enExample)
AU (1) AU2002217286A1 (enExample)
DE (1) DE60126652T2 (enExample)
ES (1) ES2282195T3 (enExample)
GB (1) GB0031315D0 (enExample)
WO (1) WO2002050031A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
SE0402284D0 (sv) * 2004-09-21 2004-09-21 Astrazeneca Ab New heterocyclic amides
JP2008518957A (ja) * 2004-11-04 2008-06-05 メルク エンド カムパニー インコーポレーテッド ナイアシン受容体作動薬、そのような化合物を含んでいる組成物及び治療方法
AU2006302174B2 (en) * 2005-10-06 2013-06-20 Exelixis, Inc. Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3
UY30048A1 (es) * 2005-12-23 2007-07-31 Astrazeneca Ab Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
EP2013169B1 (en) * 2006-04-24 2012-08-22 Merck Canada Inc. Indole amide derivatives as ep4 receptor antagonists
TWI433839B (zh) * 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
WO2008067532A2 (en) * 2006-11-30 2008-06-05 The Johns Hopkins University Antagonists of pge2 ep3 receptors
CA2672631A1 (en) 2006-12-15 2008-06-19 Glaxo Group Limited Benzamide derivatives as ep4 receptor agonists
GB0701970D0 (en) * 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
WO2009005076A1 (ja) * 2007-07-03 2009-01-08 Astellas Pharma Inc. アミド化合物
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
PL2565191T3 (pl) * 2008-05-14 2015-03-31 Astellas Pharma Inc Pochodne kwasu 4-(indol-7-ilokarbonyloaminometylo)cykloheksanokarboksylowego jako antagoniści receptora EP4 użyteczni do leczenia przewlekłej niewydolności nerek lub nefropatii cukrzycowej
WO2010087425A1 (ja) 2009-01-30 2010-08-05 国立大学法人京都大学 前立腺癌の進行抑制剤および進行抑制方法
EP2488025A4 (en) * 2009-10-15 2013-04-03 Childrens Medical Center SEPIAPTERIC INTREDUCTASE INHIBITION FOR PAIN TREATMENT
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
NZ630875A (en) * 2013-03-15 2017-12-22 Plexxikon Inc Heterocyclic compounds and uses thereof
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
TW201900613A (zh) * 2017-05-22 2019-01-01 日商小野藥品工業股份有限公司 Ep 拮抗劑
AU2018348241B2 (en) 2017-10-13 2023-01-12 Opna Bio SA Solid forms of a compound for modulating kinases
KR20230107228A (ko) 2020-11-13 2023-07-14 오노 야꾸힝 고교 가부시키가이샤 Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4251446A (en) * 1977-03-01 1981-02-17 Sterling Drug Inc. Phthalide compounds, processes and marking systems
US4322352A (en) * 1979-04-04 1982-03-30 Sterling Drug Inc. Indolyl phthalide compounds
JPS62138469A (ja) * 1985-12-11 1987-06-22 Yoshitomi Pharmaceut Ind Ltd インド−ル誘導体
US5075313A (en) * 1990-09-13 1991-12-24 Eli Lilly And Company 3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof
GB9022785D0 (en) * 1990-10-19 1990-12-05 Merck Sharp & Dohme Therapeutic agents
EP0868178A4 (en) * 1995-12-14 2000-03-29 Merck & Co Inc GONADOTROPIN RELEASING HORMON ANTAGONISTS
JP2000516958A (ja) * 1996-08-26 2000-12-19 ジェネティックス・インスチチュート・インコーポレーテッド ホスホリパーゼ酵素の阻害剤
JPH1171336A (ja) * 1997-06-25 1999-03-16 Mitsubishi Chem Corp アミド誘導体
US6342516B1 (en) * 1998-07-31 2002-01-29 Nippon Soda Co., Ltd. Phenylazole compounds, process for producing the same and drugs for hyperlipemia
US6437146B1 (en) * 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
CA2346038A1 (en) * 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for inhibiting bone resorption
GB9902455D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
CA2420042A1 (en) * 2000-08-22 2003-02-18 Mikio Ogawa Carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical agents comprising the same as active ingredient
US7157487B2 (en) * 2000-12-28 2007-01-02 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors

Also Published As

Publication number Publication date
AU2002217286A1 (en) 2002-07-01
JP2004517098A (ja) 2004-06-10
ATE353875T1 (de) 2007-03-15
EP1343757B1 (en) 2007-02-14
DE60126652T2 (de) 2008-02-28
DE60126652D1 (de) 2007-03-29
ES2282195T3 (es) 2007-10-16
US7288564B2 (en) 2007-10-30
WO2002050031A1 (en) 2002-06-27
EP1343757A1 (en) 2003-09-17
GB0031315D0 (en) 2001-02-07
US20040092569A1 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
JP4460830B2 (ja) インドール誘導体
JP4397586B2 (ja) Ｅｐ４受容体に結合するナフタレン誘導体
JP4398150B2 (ja) ベンゾ（ｆ）イソインドール誘導体およびそのＥＰ４受容体リガンドとしての使用
CN102149384B (zh) 作为ep4受体拮抗剂的杂环酰胺衍生物
CN102918034B (zh) 多取代芳族化合物作为凝血酶的抑制剂
CN106536480B (zh) 吡咯烷-2,5-二酮衍生物、药物组合物及用作ido1抑制剂的方法
US10195186B2 (en) N-substituted-5-substituted phthalamic acids as sortilin inhibitors
TWI433672B (zh) 吲唑化合物
WO2016041489A1 (zh) 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法
KR101311757B1 (ko) 2-아미노-7,8-디히드로-6ｈ-피리도［4,3-ｄ］피리미딘-5-온
PT3013814T (pt) Compostos de tetrahidrocarbazol e carbazol carboxamida substituídos úteis como inibidores de quinases
TW202041498A (zh) 抑制ｐｇｅ２／ｅｐ４信號傳導的化合物、其製備方法及其在醫藥上的應用
TWI640510B (zh) Ｃｘｃｒ７受體調節劑
CN1064269A (zh) 4-嘧啶酮类衍生物，它们的制备方法以及它们在治疗中的应用
CN113557236B (zh) 一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物
JP5893155B2 (ja) Ｃｒｔｈ２受容体拮抗薬としての窒素含有縮合環式化合物
JPH05331164A (ja) アンジオテンシンｉｉ拮抗性イソインドール誘導体
CN1490329A (zh) 咪唑啉取代的苯氧乙酰寡肽类衍生物，它们的合成及在医学中的应用
JP2007509039A (ja) シクロペンテン化合物
CN1291190A (zh) 5-取代的嘧啶－2－基氧基羧酸衍生物及其制法和作为内皮肽拮抗剂的用途
JP2005510475A (ja) テトラヒドロイソキノリン、それらの製造方法、および麻酔薬としてのそれらの使用
EP1486497A1 (en) Novel pyridone derivative
WO1991000275A1 (fr) Composes de butane ou leurs sels et leurs utilisations en medecine
HK1162301A (en) Heterocyclic amide derivatives as ep4 receptor antagonists
HK1093065B (en) Indole derivatives with apoptosis-inducing effect

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080902

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20080903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081126

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100119

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100215

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130219

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140219

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees